ATLANTA — It’s CAR-T Sunday at the American Society of Hematology’s annual meeting, where researchers representing Gilead Sciences (GILD), Novartis (NVS) and Bluebird Bio (BLUE) are addressing the assembled media horde.

Here’s your quick summary: The complete remission rate to Gilead’s Yescarta remains durable after more than one year of follow up. There are no surprises in the details from the previously announced (and positive) JULIET study of Novartis’ Kymriah in aggressive lymphoma. And the updated overall response to Bluebird’s BB2121 in multiple myeloma is now one patient short of 100 percent. No longer perfect, but very close.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy